The development of platinum compounds and their possible combination.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2006-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CRITREVONC.2006.02.003PMID 16806960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

  2005cited by this paper
• Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.

  2005cited by this paper
• Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

  2005cited by this paper
• Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.

  2005cited by this paper
• High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

  2005cited by this paper
• [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].

  2005cited by this paper
• Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

  2005cited by this paper
• Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines

  2004cited by this paper
• Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

  2004cited by this paper
• Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).

  2004cited by this paper
• Randomized Phase II Trial of Concomitant Chemoradiotherapy Using Weekly Carboplatin or Daily Low‐Dose Cisplatin for Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

  2004cited by this paper
• Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).

  2004cited by this paper
• Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

  2004cited by this paper
• Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Protein interactions with platinum-DNA adducts: from structure to function.

  2004cited by this paper
• Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase

  2004cited by this paper
• Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.

  2004cited by this paper
• Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells

  2003cited by this paper
• Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

  2003cited by this paper
• Toxicity of platinum compounds

  2003cited by this paper
• Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors.

  2003cited by this paper
• Particular aspects of platinum compounds used at present in cancer treatment.

  2002cited by this paper
• Cellular and molecular pharmacology of oxaliplatin.

  2002cited by this paper
• Oxaliplatin: A Review of Evolving Concepts

  2002cited by this paper
• Extra‐cellular thiol metabolism in clones of human metastatic melanoma with different gamma‐glutamyl transpeptidase expression: Implications for cell response to platinum‐based drugs

  2002cited by this paper
• Trans-platinum complexes as anticancer drugs: recent developments and future prospects.

  2002cited by this paper
• A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

  2002cited by this paper
• [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].

  2001cited by this paper
• Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.

  2001cited by this paper
• [Pharmacokinetic properties of platinium derivatives].

  2001cited by this paper
• Cisplatin resistance and oncogenes - a review

  2000cited by this paper
• Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin

  2000cited by this paper
• High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).

  2000cited by this paper
• Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

  2000cited by this paper
• Synthesis, Structure, Biological Activity, and DNA Binding of Platinum(II) Complexes of the Type trans-[PtCl(2)(NH(3))L] (L = Planar Nitrogen Base). Effect of L and Cis/Trans Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally Platinated DNA.

  1999cited by this paper
• Erratum: A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system (Molecular Pharmacology (1999) 55 (528-534))

  1999cited by this paper
• A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.

  1999cited by this paper
• Substitution and Reduction of Platinum(IV) Complexes by a Nucleotide, Guanosine 5'-Monophosphate.

  1999cited by this paper
• Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

  1999cited by this paper
• Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.

  1999cited by this paper
• The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma.

  1999cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cited by this paper
• Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2].

  1998cited by this paper
• Carboplatin versus cisplatin in solid tumors: an analysis of the literature.

  1998cited by this paper
• Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).

  1998cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998cited by this paper
• Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells.

  1998cited by this paper
• Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

  1998influential reference
• Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

  1997cited by this paper
• Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

  1997cited by this paper
• Modulation of Nucleotide Binding of trans Platinum(II) Complexes by Planar Ligands. A Combined Proton NMR and Molecular Mechanics Study.

  1997cited by this paper
• Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II).

  1997cited by this paper
• Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

  1997cited by this paper
• Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

  1997cited by this paper
• Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.

  1997cited by this paper
• Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.

  1997cited by this paper
• Lobaplatin in advanced urothelial tract tumors

  1997cited by this paper
• Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

  1997cited by this paper
• A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma

  1997cited by this paper
• Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group.

  1996cited by this paper
• A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

  1996cited by this paper
• Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordination.

  1996cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent.

  1995cited by this paper
• Phase II Trial of CHIP for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate: A Southwest Oncology Group Study

  1995cited by this paper
• Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.

  1995cited by this paper
• DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines

  1995cited by this paper
• Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

  1994cited by this paper
• Phase II Trial of Amonafide for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate: A Southwest Oncology Group Study

  1994cited by this paper
• A phase II study of carboplatin and cisplatin in advanced ovarian cancer.

  1994cited by this paper
• New platinum agents. A comparison in ovarian cancer.

  1994cited by this paper
• New Platinum Agents

  1994cited by this paper
• Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.

  1994cited by this paper
• Combined carboplatin and cisplatin. Limited Prospects for Dose Intensification

  1993cited by this paper
• Synthesis, characterization, and anticancer activities of the first platinum complexes from sucrose.

  1993cited by this paper
• Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

  1993cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.

  1993cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• Multicenter phase II study of spiroplatin.

  1992cited by this paper
• The use of Taq DNA polymerase to determine the sequence specificity of DNA damage caused by cis-diamminedichloroplatinum(II), acridine-tethered platinum(II) diammine complexes or two analogues.

  1992cited by this paper
• Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.

  1991cited by this paper
• Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.

  1991cited by this paper
• Preparation, characterization, and anticancer activity of a series of cis-PtCl2 complexes linked to anthraquinone intercalators.

  1991cited by this paper
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

  1991cited by this paper
• cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents.

  1990cited by this paper
• Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.

  1990cited by this paper
• Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

  1990cited by this paper
• Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione inside human red blood cells, studied by 1H and 15N-[1H] DEPT NMR.

  1990cited by this paper
• Advances in platinum cancer chemotherapy

  1988cited by this paper
• Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.

  1987cited by this paper
• Rationale for development of platinum analogs.

  1979cited by this paper
• The successful regression of large solid sarcoma 180 tumors by platinum compounds.

  1970cited by this paper

• Combined Effects of Curcumin and Carboplatin on Mitochondrial Depolarization and Caspase Activation in Human Lung Adenocarcinoma Cells

  2025cites this paper
• Platinum‐Based Chemotherapeutics in the Modern Era: From Classical DNA‐Targeting Mechanisms to Next‐Generation Innovations in Cancer Therapy

  2025cites this paper
• A fight against Cancer with Advancement of Schiff base metal complexes: Future Prospects

  2024cites this paper
• Novel biologically active paddlewheel-like palladium thiocyanate complex catalyzed cyanation of alkyl bromide utilizing Q-tube system: A green perspective

  2024cites this paper
• Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic N-Heterocycles as Bridging Ligands

  2024cites this paper
• Dorsal root ganglion inflammation by oxaliplatin toxicity: DPEP1 as possible target for peripheral neuropathy prevention

  2024cites this paper
• An overview of advancement of organoruthenium(II) complexes as prospective anticancer agents

  2023cites this paper
• Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer

  2022influential citation
• Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.

  2022cites this paper
• Conventional Chemotherapy Nephrotoxicity.

  2021cites this paper
• Comparisons of segment-specific toxicity of platinum-based agents and cadmium using S1, S2, and S3 cells derived from mouse kidney proximal tubules.

  2021cites this paper
• Synthesis, Characterization and Antiproliferative Evaluation of Pt(II) and Pd(II) Complexes with a Thiazine-Pyridine Derivative Ligand

  2021cites this paper
• Antioxidant Effects of Pinus eldarica Extracts Against Cisplatin-induced Cytotoxicity in Human Hepatoma (HepG2) Cell Line

  2021cites this paper
• Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments

  2021cites this paper
• Transient receptor potential ankyrin 1 mediates cisplatin-induced apoptosis in renal tubular cells via calcium-dependent signaling pathway.

  2021cites this paper
• Vibrational frequencies and intramolecular force constants for cisplatin: assessing the role of the platinum basis set and relativistic effects

  2021influential citation
• Evaluation of the Anticancer and DNA-Binding Characteristics of Dichloro(diimine)zinc(II) Complexes

  2021cites this paper
• Facile entry to germanate and stannate complexes [(η6-arene)RuCl(η2-dppm)]+[ECl3]- (E = Ge, Sn) as potent anti-cancer agents

  2020cites this paper
• A Histopathological Study of Cisplatin-induced Acute Vascular Injuries in Vital Organs and Protective Effect of Achillea millefolium

  2020cites this paper
• Metallodrugs for the treatment of Trypanosomatid diseases: recent advances and new insights.

  2020cites this paper
• Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents

  2020cites this paper
• Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury.

  2020cites this paper
• Vitamin E protects against cisplatin-induced genotoxicity in human lymphocytes.

  2020cites this paper
• Transition metal complexes as imaging or therapeutic agents for neurodegenerative diseases.

  2020cites this paper
• Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer

  2019cites this paper
• Current Concepts in the Use of Cisplatin: A Historical Perspective and Its Recent Advances in the Treatment of Non-Small Cell Lung Cancer

  2019cites this paper
• Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool

  2019cites this paper
• Heterobimetallic Ru(μ-dppm)Fe and homobimetallic Ru(μ-dppm)Ru complexes as potential anti-cancer agents

  2019cites this paper
• Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies

  2019cites this paper
• Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment

  2019cites this paper
• Evaluation of the protective effects of amifostine and melatonin against cisplatin induced testis injury via oxidative stress and apoptosis in rats.

  2019cites this paper
• Chronic effects of platinum(IV) complex and its diamine ligand on rat heart function: comparison with cisplatin

  2019cites this paper
• Probiotic bacteria attenuates cisplatin-induced nephrotoxicity through modulation of oxidative stress, inflammation and apoptosis in rats

  2019cites this paper
• Studies of the anticancer activities of ruthenium(II) polypyridyl complexes toward human hepatocellular carcinoma BEL-7402 cells

  2019cites this paper
• Mechanistic insight on the chemistry of potential Pt antitumor agents as revealed by collaborative research performed in Kragujevac and Erlangen

  2019cites this paper
• Electromagnetic Field Could Protect SH-SY5Y Cells Against Cisplatin Cytotoxicity, But Not MCF-7 Cells

  2018cites this paper
• Synthesis, cytotoxic activity and DNA-binding properties of copper(II) complexes with terpyridine

  2018cites this paper
• The Potential Impact of Magnesium Supplementation on Cisplatin-Induced Nephrotoxicity in Adult Male Albino Rats

  2017cites this paper
• Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.

  2017cites this paper
• Platinum derivatives: a multidisciplinary approach.

  2017cites this paper
• Microwave-assisted synthesis of mixed ligands organotin(IV) complexes of 1,10-phenanthroline and l-proline: Physicochemical characterization, DFT calculations, chemotherapeutic potential validation by in vitro DNA binding and nuclease activity.

  2017cites this paper
• Introduction Platinum derivatives : a multidisciplinary approach

  2017cites this paper
• Urinary TIMP2⋅IGFBP7 for the prediction of platinum-induced acute renal injury

  2017cites this paper
• Crystal structure and theoretical investigation of bis(cis-1,2-diaminocyclohexane)zinc(II) tetrachloridozincate(II)

  2017cites this paper
• Expression of RNA-binding motif 10 is associated with advanced tumor stage and malignant behaviors of lung adenocarcinoma cancer cells

  2017cites this paper
• Quality Standardization and Nephroprotective Effect of Garcinia pedunculata Roxb. Fruit rind

  2017cites this paper
• Urinary TIMP 2 ⋅ IGFBP 7 for the prediction of platinum-induced acute renal injury

  2017cites this paper
• Natural Luteolin from Methanolic Extract of Malaysian Brucea javanica Leaves Induces Apoptosis in HeLa Cell Lines

  2016cites this paper
• New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation

  2016influential citation
• Punica granatum (pomegranate) leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in non-small cell lung cancer in vitro.

  2016cites this paper
• Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin

  2016cites this paper
• Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer

  2015cites this paper
• New application of carbon nanotubes in haemostatic dressing filled with anticancer substance.

  2015cites this paper
• Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis.

  2015cites this paper
• Compostos coordenados híbridos de platina no tratamento do câncer

  2015influential citation
• Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration

  2015cites this paper
• Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro.

  2015cites this paper
• Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1

  2015cites this paper
• Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System

  2015cites this paper
• Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death

  2015cites this paper
• Renoprotective effects of antioxidants against cisplatin nephrotoxicity

  2014cites this paper
• Mitochondrial DNA haplogroup-dependence of drugs and xenobiotics toxicity

  2014cites this paper
• Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells

  2014cites this paper
• Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.

  2014cites this paper
• Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells

  2014cites this paper
• Nanotube-mediated efficiency of cisplatin anticancer therapy

  2014cites this paper
• A biodegradable polymer platform for co-delivery of clinically relevant oxaliplatin and gemcitabine.

  2014cites this paper
• Lobaplatin arrests cell cycle progression, induces apoptosis and alters the proteome in human cervical cancer cell Line CaSki.

  2014cites this paper
• Development and characterization of pro-apoptotic drug candidates for anticancer drug discovery

  2013cites this paper
• Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

  2013cites this paper
• Urinary neutrophil gelatinase‐associated lipocalin levels predict cisplatin‐induced acute kidney injury better than albuminuria or urinary cystatin C levels

  2013cites this paper
• Conventional Cancer Treatment

  2013cites this paper
• Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

  2013cites this paper
• The study of interactions between antitumor effective heavy metal complexes with biomacromolecules using molecular biophysics methods

  2013cites this paper
• Metabolic and mitochondrial remodelling in cisplatin resistance: studies on ovarian cancer cells and derived cytoplasmic hybrids

  2013cites this paper
• What’s in a Pill? On the Informational Enrichment of Anti-Cancer Drugs

  2013cites this paper
• A relativistic DFT methodology for calculating the structures and NMR chemical shifts of octahedral platinum and iridium complexes.

  2013cites this paper
• The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.

  2013cites this paper
• Efficacy of Goshajinkigan for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients

  2013cites this paper
• Factors affecting biological effects of metallodrugs

  2013cites this paper
• Synthesis and cytotoxicity of dinuclear platinum(II) complexes of (1S, 3S)-1,2,3,4-tetrahydroisoquinolines

  2013cites this paper
• Chapter 1 Conventional Cancer Treatment

  2013cites this paper
• Macromolecular platinum-drugs based on statistical and block copolymer structures and their DNA binding ability

  2013cites this paper
• Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells?

  2013cites this paper
• Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE.

  2012cites this paper
• Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

  2012cites this paper
• Platinum-modified adenines: unprecedented protonation behavior revealed by NMR spectroscopy and relativistic density-functional theory calculations.

  2012cites this paper
• Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro.

  2012influential citation
• Understanding how the platinum anticancer drug carboplatin works: From the bottle to the cell

  2012cites this paper
• Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers.

  2012cites this paper
• Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets

  2012cites this paper
• Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect

  2012cites this paper
• Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action and Metabolism

  2011cites this paper
• Synthesis, characterization, structures and cytotoxic activity of palladium(II) and platinum(II) complexes containing bis(2-pyridylmethyl)amine and saccharinate

  2011cites this paper
• Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies.

  2011cites this paper
• The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum.

  2011cites this paper
• DeterminationofPlatinumOriginatingfrom CarboplatininHumanUrineandCanineExcretion ProductsbyInductivelyCoupledPlasmaMass Spectrometry

  2011cites this paper
• Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines.

  2011cites this paper
• Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.

  2011cites this paper
• Studies on two new mixed ligand platinum compounds with a trans-geometry.

  2010cites this paper